Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.48 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351483 | 1.00 | LPL (0.48) | LPLLIPGF11DGAT1FFAR1 | |
| SCHEMBL600819 | 0.88 | CYP2A6 (0.38) | LPLLIPGALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13593443 | 0.85 | LPL (0.38) | LPLLIPGF11DGAT1FFAR1 | |
| SCHEMBL30590709 | 0.83 | LPL (0.44) | LPLLIPGF11DGAT1FFAR1 | |
| SCHEMBL27949981 | 0.81 | LPL (0.33) | LPLLIPGF11ALDH1A1CYP1A2 | |
| SCHEMBL15496389 | 0.81 | LPL (0.47) | LPLLIPGALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5529229 | 0.81 | LIPG (0.47) | LPLLIPGALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL29653662 | 0.81 | LIPG (0.47) | LPLLIPGALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20289678 | 0.81 | LPL (0.34) | LPLLIPGF11DGAT1FFAR1 | |
| SCHEMBL32689814 | 0.81 | ELANE (0.39) | LPLLIPGALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114713284-A | Organic conjugated polymer photocatalyst containing B ← N coordination bond, preparation method and application | 兰州大学 | 2022-07-08 | — | — | CN | claimed |
| CN-106532120-A | Non-aqueous electrolyte and lithium secondary battery of using same | 广州天赐高新材料股份有限公司 | 2017-03-22 | — | — | CN | claimed |
| EP-4743455-A1 | SARM1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12635401-B2 | Metal complexes | UDC Ireland (IE) | 2026-05-19 | — | — | US | disclosed |
| US-20260132126-A1 | IMIDAZOLE DERIVATIVES | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2006065217-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2005123673-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123675-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12635401-B2 | Metal complexes | SCO2, SOD1, NR4A1 | LPL 3906/4885LIPG 4145/4885F11 1722/4885 |
| US-20260132126-A1 | IMIDAZOLE DERIVATIVES | ADRA1A, ADRA1D, ADRB1 | LPL 3517/4885LIPG 2144/4885F11 966/4885 |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | LPL 4144/4885LIPG 2758/4885F11 1842/4885 |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, CBR1, CNR1 | LPL 4105/4885LIPG 3906/4885F11 2925/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | LPL 4355/4885LIPG 4527/4885F11 781/4885 |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | LPL 414/4885LIPG 108/4885F11 1264/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | LPL 4478/4885LIPG 3355/4885F11 1089/4885 |
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | LPL 2409/4885LIPG 2267/4885F11 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.